---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-003931"
form_type: "8-K"
ticker: "EDSA"
cik: "0001540159"
company_name: "Edesa Biotech, Inc."
filed_at: "2026-06-05T13:25:18+00:00"
generated_at: "2026-06-05T13:26:10.605509+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Edesa Biotech: paridiprubart shows 32% relative mortality reduction in AKI/ARDS patients

## Summary
- Exploratory Phase 3 data: paridiprubart + SOC reduced 28-day mortality to 33% vs 49% placebo (p<0.005).
- MAKE30 composite endpoint incidence reduced to 41% from 53% (23% relative reduction, p<0.005).
- AKI cohort of 101 severely ill patients (90% moderate-to-severe ARDS, ~50% on ventilation/ECMO).
- Paridiprubart well tolerated; no significant differences in adverse events vs placebo.
- Data presented at ERA Congress 2026; results exploratory and require confirmatory studies.

## SEC filing metadata
- accession: 0001171843-26-003931
- form_type: 8-K
- ticker: EDSA
- cik: 0001540159
- company_name: Edesa Biotech, Inc.
- filed_at: 2026-06-05T13:25:18+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1540159/000117184326003931/0001171843-26-003931-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1540159/000117184326003931/f8k_060226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-003931
- JSON: https://secwatch.observer/filing/0001171843-26-003931.json
- Plain text: https://secwatch.observer/filing/0001171843-26-003931.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.